cyrilzakka/clinical-trials huggingface dataset:
The Comprehensive Assessment in Children After Surgical Treatment of Patellar Recurrent Dislocation.

The aim of this prospective study is to assess extension apparatus function of the knee based on clinical, radiological, isokinetic and gait analysis data in patients after surgical treatment. There will be used physical examination, Lysholm-Tegner and Kujala scale for clinical assessment. Merchant and lateral X-ray pictures will be analysed for patellar position verification along with isokinetic and gait evaluation to produce conclusions referring to efficacy of the treatment. All subjects included in the study were treated with mpfl reconstruction. Follow-up longer than 2 years in all cases, about 45 patients included.

Recurrent patellar dislocation occurs mostly in adolescents. Recently medial patellofemoral ligament reconstruction has become treatment of choice in most cases. There is still insufficient literature to assess the operative treatment results according to functional testing.

The aim of this prospective study is to assess extension apparatus function of the knee based on clinical, radiological, isokinetic and gait analysis data in patients after surgical treatment. There will be used physical examination, Lysholm-Tegner and Kujala scale for clinical assessment. Merchant and lateral X-ray pictures will be analysed for patellar position verification along with isokinetic and gait evaluation to produce conclusions referring to efficacy of the treatment. All subjects included in the study were treated with mpfl reconstruction with gracilis tendon harvesting. Follow-up provided is longer than 2 years in all 45 cases planned to enroll. All subject are to be mailed and invited to check-up visit including analysis of parameters mentioned above. Soon after data collection text of the publication will be made. The results will be discussed with recent literature and conclusions will be made.

Eligibility Criteria:
Inclusion Criteria:

* age \<18 yo
* recurrent patellar dislocation
* ready for follow-up

Exclusion Criteria:

* age \<18 yo
* osteochondral fracture
* habitual dislocation
Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Clinical trial with medical devices, post-authorization, parallel, single-blind, randomized, comparative, prospective to study how afects the quality of life the use of ocular eye drops on patients with dry eye symptomatology and age-related loss of visual acuity.

Secondary purposes: efects on the dry eye symptomatology, efect on visual acuity and treatment adherence.


Eligibility Criteria:
Inclusion Criteria:

* Subjects between the ages of 50 and 70.
* Subjects with initial or slight changes characteristic of cataracts (grade 1-3 according to LOCS III classification).
* Subjects with dry eye symptoms.
* Confirmation of senile cataract diagnosis according to medical history and clinical observations, bilateral.
* Visual acuity equal to or greater than (0.6) in both eyes (with the best correction).
* Cataracts without the need for surgical intervention in the near future (1 year) based on the visual needs of the patient and ocular symptomatology.
* Subjects that have not undergone cataract surgery.
* Cases that do not accept surgery (weak corneas, high degree of myopia, sensitivity to light, severe dryness of the eyes or by their own decision).
* Subjects who agree to sign the IC (Informed Consent).

Exclusion Criteria:

* Subjects with eye diseases such as glaucoma or diabetic retinopathy.
* Previous laser photocoagulation of the retina.
* Previous corneal or anterior segment surgery or previous corneal scars that may interfere with visualization or photographs.
* Presence of mature cataracts (grade 4-5/6 according to LOCS III classification) in both eyes.
* Candidates for surgery in the following year.
* Subjects with monocular aphakia (absence of crystalline lens) or secondary cataracts (associated with steroid use, local or total irradiation, local inflammation or degenerative processes, ocular trauma).
* Subjects with known hypersensitivity to any component of ophthalmic treatment.
* Subjects treated with drugs that may interfere with the evolution of the disease under study.
* Subjects who wear contact lenses.
* Pregnant women.
* Breastfeeding women.
* Subjects who have participated in another clinical trial within the last 30 days.
* Subjects with linguistic or psychological incapacity to understand and sign the CI.
Haemodynamic Abnormalities Recorded With Cardiac Catheterization Along With Body's Surface Micro-accelerometers (KT-KCG)

The ballistocardiography (BCG) and the seismocardiography (SCG) are old techniques recording the vibrations at the skin level generated by the acceleration and displacement of the blood and cardiac mass at each cardiac contraction. The former records the acceleration near the subject's center of mass, the latter at the local chest wall. So far, the unclear physiological origin of those acceleration signals has led to important ambiguities in their scientific and clinical interpretation. Therefore, several ongoing studies would aim to highlight the physiological genesis of those acceleration-induced signals.

Indeed, the main objective of this study is to correlate the BCG and SCG signals recorded at the body surface with several haemodynamic parameters recorded invasively during a cardiac catheterisation, pulmonary pressure, wedge pressure, cardiac output to cite a few.

Patients suffering from severe heart failure regardless of the etiology will undergo a cardiac catheterization as required by their medical condition.

The SCG and BCG signals will be recorded simultaneously to the catheterization by the mean of an unintrusive and friendly device consisting of two houses, the first one placed on sternum and the second one in the lumbar column. The device will record a continuous tracing synchronized with the intracavitary pressure profiles recorded during the invasive procedure.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 y.o. to 80 y.o.
* Heart failure

Exclusion Criteria:

* Left ventricle assistance device
* Refused participation
CIK Treatment for HCC Patient Underwent Radical Resection

This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included. The patients will be randomized to group A (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer treatment after resection of HCC, and the randomize ratio will be 1:1.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patients over 18 years of age.
* Without any prior anti-cancer therapy.
* Patients who have a life expectancy of at least 12 weeks.
* Patients already had radical resection of HCC.

Definition of radical resection in this study:

* All tumors were moved out, with a clean resection margin.
* Number of tumors less than 3.
* Without tumor invasion of the main trunk and first branch of the portal vein, or hepatic duct, or hepatic vein.
* No hepatic hilum lymphnode metastasis.
* No distance metastasis.
* Hepatocellular carcinoma with histological diagnose.
* No major post-operative complication.
* Patients who have an performance status of 0, or 1.
* Cirrhotic status of Child-Pugh class A only.
* The following laboratory parameters:
* Patients who give written informed consent.

Exclusion Criteria:

* Previous or concurrent cancer that is distinct in primary site or histology from HCC.
* History of cardiac disease.
* Active clinically serious infections ( over grade 2 National Cancer Institute-Common Terminology Criteria for Adverse Events version 3.0)
* Known history of human immunodeficiency virus (HIV) infection
* Known Central Nervous System tumors including metastatic brain disease.
* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
* History of organ allograft.
* Known or suspected allergy to the investigational agent or any agent given in association with this trial.
* Pregnant or breast-feeding patients.
* Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
* Excluded therapies and medications, previous and concomitant:

Prior use of any anti-cancer treatment for HCC, eg. chemotherapy, radiotherapy. Antiviral treatment is allowed.
Advance Directives and End-of-life Decision Making in Intensive Care Medicine in Germany

Description of the decision making process as well as the practices of end of life care in an ICU of a German university hospital during the period when changes of German legislation occurred.

Most patients on the intensive care unit (ICU) die after an end-of-life decision (EOLD) has been made (Sprung et al. 2003). On September 1st 2009 the "advance-directives-law" was inured in Germany considering a written advance directive of an adult binding for physicians and the patient´s surrogate decision makers if it fits into the medical context (BGBL 2009). There is a lack of data describing the process and the factors associated with end-of-life-decisions in ICUs in Germany in detail.

The purpose of this observational study is to describe the decision making process as well as the practices of end of life care in an ICU of a German university hospital during a period when changes of German legislation occurred.

Eligibility Criteria:
Inclusion Criteria:

* All patients admitted to the ICU
* All patients discharged death from the ICU

Exclusion Criteria:

* All patients discharged alive from the ICU
Stress Inoculation Training (SIT): An Evidence-Based, Military Aligned Psychological Performance and Health Sustainment Prototype

The purpose of this study is to demonstrate the feasibility of augmenting existing/traditional Navy military training with the manualized SIT Core Protocol (CP) utilizing the established augmentation procedure set as measured by feasibility, utility, and satisfaction metrics (CSQ-8) and to examine the relative effectiveness of the SIT-CP by comparison to standard military training in a controlled trial examining outcomes of stress tolerance, psychological health, resilience and occupational performance in Sailors undergoing DCA Firefighting Training (pre- to post-training), while collecting implementation data.


Eligibility Criteria:
Inclusion Criteria:

* US Navy service members on Active Duty or Reserve status
* be fluent in English.
* be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
* have access to a SmartPhone, computer, or tablet to utilize and access the virtual classroom.
* agree to undergo psychometric and operational performance testing and participate in ongoing assessments throughout the study duration.
* be willing to comply with all study procedures, able to complete all assessments independently, and available for the duration of the study (with reasonable accommodations for military operational demands as they arise).

Exclusion Criteria:

* Active suicidal ideation as assessed by the Investigator at screening or as identified during the study.
* Clinically significant history of psychotic disorder, bipolar spectrum disorder, or neurodegenerative disease/dementia as assessed by the Investigator.
* Active severe substance abuse as assessed by the investigator in accordance with The Diagnostic and Statistical Manual of Mental Illnesses (DSM-5) Substance Abuse Disorder criteria, or presence of illicit substance abuse.
* They are currently undergoing another form of treatment other than supportive therapy (\>2 times per month).
* Any other condition/situation that the Investigator believes may interfere with participant safety, study conduct, or interpretation of study data.
Evaluation of Desarda Technique in Management of Complicated Inguinal Hernia

This study aims to evaluate the desarda technique in management of complicated inguinal hernia.

Desarda technique is one of the best surgical methods suitable for emergency hernia surgery repair, but there is still limited consensus. The purpose of this study is to assess the Long-term outcome of the pure tissue Desarda technique for the treatment of emergency inguinal hernias repair (Incarcerated, Irreducible, and Obstructed Patients) regarding Postoperative Complications, Groin Pain, and recurrence rate.

Surgical techniques for emergency inguinal hernia surgery remain an important less documented area. Emergency inguinal hernia can have different presentations. Incarceration is characterized by the irreducibility of contents and strangulation by the compromise of the blood supply of the contents (e.g., bowel, omentum).

Eligibility Criteria:
Inclusion Criteria:

* Age above 14 years old.
* Irreducible, incarcerated \& obstructed inguinal or inguinoscrotal hernia; unilateral or bilateral

Exclusion Criteria:

* Recurrent Hernias.
* Intra-operative finding of separated thin and/or weak external oblique aponeurosis.
The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

To evaluate the change of blood perfusion before/after the use of Endostar, discuss the time sequence of Endostar TM in treating advanced lung adenocarcinoma in normalization window period.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically newly diagnosed as unresectable and metastasis advanced lung adenocarcinoma(Stage IV, Seventh Edition of the UICC/AJCC Classification for Lung Cancer).
* At least one measurable objective tumor lesion, spiral CT or PET-CT examination: the shortest diameter ≥2cm，and no obvious necrosis
* Life expectancy ≥12weeks
* Patients receive palliative radiotherapy for bone's pain relief; patients receive radiotherapy for brain metastasis、patients after brain transfer operation or radiation therapy are allowed to enter the research.
* 18≤Patients'age \<70 years.
* Electrocolonogram (ECOG) Score:0-1.
* Granulocyte count ≥ 2.0×109/L, platelet count ≥ 100×109/L.
* Serum bilirubin within the normal range.
* Aspartate aminotransferase ( AST ), Alanine aminotransferase ( ALT ) within the normal range(if the patients is diagonosed as liver metastasis,his/her AST/ALT should not surpass 1.5 times of the normal range ).
* Serum creatinine within the normal range and creatinine clearance rate ≥60ml/min
* Compliance with research requirements and be able to follow up.
* Within 72 hours before the treatment, all women pregnant with pregnant possibility should undergo pregnancy test and get negative results.
* Patients with fertility ability should take effective contraceptive techniques.
* Sign informed consent of this clinic trial.

Exclusion Criteria:

* Lung adenocarcinoma patients who received systemic chemotherapy/thoracic radiotherapy/targeted therapy
* Received resection, cutting or aspiration within seven days
* Any unstable systemic diseases (including peptic ulcer、active infection、grade4 hypertension、unstable angina、congestive heart failure、liver, metabolic disorders or fracture、unhealing wound )
* Chronic kidney disease history(including chronic nephritis, nephrotic syndrome, Obstruction of urinary tract etc. caused by Urinary calculus)
* have to use anticoagulant drugs at the same time
* patients with obvious coagulation disorders、active bleeding and bleeding tendency
* Any other malignancies (complete cure of cervical carcinoma in situ/basal cell carcinoma/squamous cell carcinoma are excluded )happened within 5 years.
* Signifinant weight loss, weight lost during the 6 weeks more than or equal to 10%
* Patients who take bone metastasis as the only observing index
* Allergic to escherichia coli preparation
* Used Endostar before
* Lactating women
* Contraindications written on Pemetrexed、Carboplatin、Dexamethasone instructions
* Allergic to radiographic contrast agents
* In the middle or planning to attend other clinic trails
Clinical Verification of Peptide Biomarkers for Human Aging

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

The procedure of clinical study was:

1. to get plasma samples from hospital;
2. digestion of plasma protein-mixture by trypsin in lab;
3. run mass spectrometry and monitor the amount of target HSA-peptides.

Eligibility Criteria:
Inclusion Criteria:

* Cases with different ages

Exclusion Criteria:

* Cases with Diabetes Mellitus and Hepatitis B
Routine Ultrasound Screening in the Third Trimester

Late intrauterine growth restriction is infrequently diagnosed with an overall sensitivity of 40 % in low-risk pregnancies. In addition, late intrauterine growth restriction may be associated with intrauterine death and poor neonatal outcomes i.e. birth asphyxia and hospitalization in intensive care unit. The investigators hypothesis that a later third trimester routine ultrasound may be more accurate to diagnose late intrauterine growth restriction.


Eligibility Criteria:
Inclusion Criteria:

* Accurate gestational dating using crown-rump length at 11-14 weeks
* Singleton pregnancy
* Primiparity
* Normal First trimester (11-14 weeks) and second trimester (20-25 weeks) scans
* Maternal age \> 18 years
* No maternal opposition for the study

Exclusion Criteria:

* Maternal diseases i.e. chronic renal disease, hypertension, diabetes, collagen vascular disease, antiphospholipid syndrome
* Pregnancies with congenital anomalies or foetal growth restriction diagnosed before 30 weeks of gestation
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.


Eligibility Criteria:
Inclusion Criteria

Patients must have the following:

* Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria.
* Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease.
* Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.
* Signed written informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
* Stage IE Central Nervous System lymphomas.

Patients with the following are excluded:

* More than one previous treatment for lymphoma.
* Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
* Conditions that preclude obtaining an informed consent.
* Not accessible for scheduled treatment visits or follow-up.
* Stage IE Central Nervous System (CNS) lymphomas.

Prior Medication:

Excluded within 2 weeks of study entry:

* Zidovudine.
* Excluded:
* Doxorubicin dosing = or \> 300 mg/m2.

Prior Treatment:

Excluded:

* Received more than one previous treatment regimen for lymphoma.

Required:

* Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages. Different exploratory trials suggest that the combination of radiotherapy and PD-1/PD-L1 inhibitors is highly effective, especially in oligometastatic stages and if all lesions are treated with ablative radiotherapy. In addition, the role of predictive biomarkers is becoming increasingly important for future therapy algorithms. First data, also from our group, indicate clearly that dynamic changes of immune cells and their activation markers in the peripheral blood (immune matrix) can be used as predictive biomarkers. During the planned STICI-02 trial predictive immune matrix derived from the STICI01 trial (NCT03453892) will be validated in the groups of patient suffering from HNSCC (palliative), NSCLC (separately palliative and adjuvant) and "other solid tumors" (including in particular esophageal carcinomas, urothelial and renal carcinomas, small cell bronchial carcinomas and squamous cell carcinomas of the skin \[depending on the current drug approval\]). Within the framework of scientific accompanying projects, the predictive value of markers in tumor tissue and of pattern radiomics analyses will be analyzed accompanying the immunophenotyping in peripheral blood. The side effects


Eligibility Criteria:
Inclusion Criteria:

* Patients treatable for HNSCC (palliative), NSCLC (separately palliative and adjuvant) or "other solid tumour"
* Indication for system therapy with a PD-1/PD-L1 inhibitor according to clinical standards
* Patients without or with radiation of one or more metastases
* Age at least 18 years

Exclusion Criteria:

* Melanoma patients
* Fertile patients who refuse effective contraception during study treatment
* Persistent drug and/or alcohol abuse
* Patients not able or willing to behave according to study protocol
* Patients in care
* Patients that are not able to speak German
* Patients which are imprisoned according to legal or governmental order

Both gender are included into the study, a maximum age was not defined.